Prospective Evaluation for Hybrid Cardiac Procedures

  • End date
    May 12, 2025
  • participants needed
  • sponsor
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Updated on 9 December 2021
percutaneous coronary intervention
antiplatelet therapy
bypass graft
acute coronary syndrome
coronary disease
coronary revascularization
aortic valve replacement
coronary bypass


Multidisciplinary team-approach in order to offer personalized treatments represents the emerging mainstream in cardiovascular medicine. "Hybrid operative rooms" allow to offer selected heart-disease patients truly "tailored" operations.

This study wants to evaluate the effectiveness and safety of Hybrid Procedures in cardiac patients in three subgroups of patients:

  • Hybrid coronary revascularization strategy (coronary by-pass + PCI);
  • Hybrid valve and coronary disease correction (combination of surgical valve replacement and PCI);
  • Hybrid coronary and carotid artery disease treatment (combination of coronary by-pass and carotid stenting).

The investigators hypothesize that morbidity might be reduced by 50% in hybrid procedures group as compared with predicted Society of Thoracic Surgery (STS) score.


Cardiovascular medicine is actually evolving fast and multidisciplinary team-approach in order to offer personalized treatments represents the emerging mainstream. The possibility to realize combinations of treatments traditionally available only in the catheterization laboratory and in the operating room represent the rationale for "hybrid operative rooms" facilities allowing to offer selected heart-disease patients truly "tailored" operations. Such "Hybrid" management strategies usually combine transcatheter techniques and surgery (often minimally invasive) in order to combine the reduced invasiveness of the former with the effectiveness of the latter. Common examples of surgical and transcatheter combinations are: hybrid revascularization performed with coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI); combined heart valve and coronary disease treated with valve surgery and PCI; combined endo- and epicardial ablation of atrial fibrillation; thoracic aneurysms treated with endovascular stenting and surgical debranching of the arch; carotid artery stenting along with CABG. Given the relatively recent development of these techniques, indications and patient selection are yet to be defined and a productive collaboration between surgeons and interventional cardiologists is of paramount importance.

Aim of the study is to evaluate the effectiveness and safety of Hybrid Procedures in cardiac patients. Specifically, three subgroups will be analysed:

  • Hybrid coronary revascularization strategy (HCR, coronary by-pass + PCI);
  • Hybrid valve and coronary disease correction (combination of surgical valve replacement and PCI);
  • Hybrid coronary and carotid artery disease treatment (combination of coronary by-pass and carotid stenting).

The local Heart Team (cardiac surgeon, interventional cardiologist, clinical cardiologist and anaesthetist) will decide which patients will be referred for hybrid treatment. Typically, this happens when the Heart Team feels that hybrid treatment could reduce the overall risk of a combined procedure.

The patient population consists of adult patients with:

  • Multi-vessel coronary artery disease (CAD) involving the left main and/or the left anterior descending artery with indication for revascularization;
  • Severe, symptomatic valvular disease and CAD with indication for revascularization;
  • Significant unilateral carotid stenosis and CAD with indication for revascularization.

In a previous data review board on the Heart Team activity, we recognized that 10% of discussed patients are referred for hybrid procedures (HP) and that observed operative mortality was strongly lower than that predicted by STS and EuroSCORE (2.5% versus 10.1% and 5.9%, respectively). Morbidity was not prospectively investigated. For sample size estimation, the investigators hypothesized that Morbidity might be reduced by 50% in HP group as compared with predicted STS. The mean expected STS morbidity estimated in the study population is 32.57%. Accordingly, a total number of 111 patients with an alpha error of 5% and a beta error of 20% has been calculated to be needed to test this hypothesis.

Condition Cardiac Disease, Coronary heart disease, Carotid Occlusion, heart diseases, Myocardial Ischemia, VALVULAR HEART DISEASE, Carotid Artery Disease, Heart disease, CAROTID ARTERY DISEASE, Left Anterior Descending Coronary Artery Stenosis, Arterial Occlusive Disease, Heart Valve Disease, Cardiac Ischemia, Cardiovascular Disease, cardiac diseases, Heart Disease, Carotid Artery Occlusion, Carotid Artery Stenosis, Coronary Artery Disease, Left Main Coronary Artery Disease, cardiac disorder, Occlusions, cardiac disorders, heart disorder
Treatment Coronary Artery Bypass Grafting, Percutaneous coronary intervention, Carotid Artery Stenting, Surgical valve replacement, Surgical valve replacement
Clinical Study IdentifierNCT05143671
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Last Modified on9 December 2021


Yes No Not Sure

Inclusion Criteria

Signed informed consent, inclusive of release of medical information
Age 18 years
CAD with indication for revascularization
Coronary anatomy as follows
Multivessel-CAD involving the left anterior descending (LAD) (proximal or mid) and/or the left main (LM) (ostial, mid-shaft or distal) with at least one further epicardial coronary artery requiring treatment (LCX or RCA), OR
Single vessel disease involving the LAD and a major diagonal, both requiring independent revascularization with at least one stent
Severe aortic stenosis/insufficiency and/or mitral stenosis/insufficiency requiring surgery, with CAD (involving one or more vessels), suitable for PCI
CAD with indication for revascularization with severe unilateral carotid stenosis (>85%)
Ability to tolerate, and no plans to interrupt dual antiplatelet therapy (DAPT) for
At least 6 months in presentation was stable CAD
At least 12 months if presentation was a biomarker-positive acute coronary syndrome (ACS)
Willing to comply with the follow-up required by the protocol

Exclusion Criteria

Previous cardiac surgery of any kind
Previous thoracic surgery involving the left pleural space (if a left thoracotomy approach is planned)
Complicated or unsuccessful PCI within 30 days prior
Total occlusion (TIMI 0 or 1 flow) of the LM or LAD
Cardiogenic shock at time of screening
Any prior lung resection
End-stage renal disease on dialysis
Extra-cardiac illness that is expected to limit survival to less then 5 years
Allergy or hypersensitivity to any of the study drugs or devices used in protocol
Patient unable to give informed consent or potentially noncompliant with the study protocol, in the judgement of the investigator
Pregnant at time of screening, or unwilling to use effective birth control measures while dual antiplatelet therapy is required
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note